Profund Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Profund Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,179	Closed	-$303K	–	1079
2023 Q1	$303K	Buy	+4,179	New	+$405K	0.02%	721

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Profund Advisors's ATRA Position: Q2 2023 in Review

Profund Advisors sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 4,179 shares — an estimated $303K sold.

Profund Advisors first reported a position in ATRA in Q1 2023 and held it in 1 quarter. The position peaked at $303K in Q1 2023. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

Profund Advisors reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Profund Advisors sold 4,179 Atara Biotherapeutics shares in Q2 2023, an estimated $303K.
Profund Advisors first reported a position in Atara Biotherapeutics in Q1 2023 and held it in 1 quarter.
Profund Advisors's Atara Biotherapeutics position peaked at $303K in Q1 2023.
118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Profund Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.